Evidence map›Paper›PMID 36994755›Full record

ArticleAnnals of surgery2023

Minimally Invasive Versus Open Liver Resections for Hepatocellular Carcinoma in Patients With Metabolic Syndrome.

Giammauro Berardi, Tommy Ivanics, Gonzalo Sapisochin, Francesca Ratti, Carlo Sposito, Martina Nebbia, Daniel M D'Souza, Franco Pascual, Samer Tohme, Francesco Enrico D'Amico and 37 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

47 authors.

Giammauro BerardiDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Tommy IvanicsDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Gonzalo SapisochinDepartment of Surgery, University of Toronto, Toronto, ON, Canada.
Francesca RattiDivision, San Raffaele Hospital, Hepatobiliary Surgery Milan, Italy.
Carlo SpositoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Martina NebbiaDepartment of Surgery, Massachusetts General Hospital, Boston, MA.
Daniel M D'SouzaDepartment of Surgery, McMaster University, Hamilton, ON, Canada.
Franco PascualDepartment of Surgery, Paul Brousse Hospital, Villejuif, Paris, France.
Samer TohmeDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Francesco Enrico D'AmicoDepartment of Surgery, University of Padua, Padua, Italy.
Remo AlessandrisDepartment of Surgery, University of Padua, Padua, Italy.
Valentina PanettaL'altrastatistica Consultancy and Training, Biostatistics Department, Rome, Italy.
Ilaria SimonelliL'altrastatistica Consultancy and Training, Biostatistics Department, Rome, Italy.
Celeste Del BassoDepartment of Surgery, San Camillo Forlanini Hospital, Rome, Italy.
Nadia RussolilloDepartment of Surgery, Mauriziano Hospital, Turin, Italy.
Guido FiorentiniDepartment of Surgery, Mayo Clinic, Rochester, NY.
Matteo SerenariHepatobiliary surgery and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Fernando RotellarHepatobiliary and Liver Transplantation Unit, Department of Surgery, University Clinic, Universidad de Navarra, Pamplona, Spain; Institute of Health Research of Navarra (IdisNA), Pamplona, Spain.
Giuseppe ZimittiDepartment of surgery, Poliambulanza Foundation Hospital, Brescia, Italy.
Simone FamularoDepartment of General Surgery, Humanitas University and Research Hospital, IRCCS, Milan, Italy.
Daniel HoffmanDepartment of Surgery, University of California San Francisco, San Francisco, CA.
Edwin OnkendiDepartment of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX.
Santiago Lopez-BenDepartment of Surgery, Hospital Universitari Dr Josep Trueta de Girona, Girona, Spain.
Celia CaulaDepartment of Surgery, Hospital Universitari Dr Josep Trueta de Girona, Girona, Spain.
Gianluca RompianesiDivision of HPB, Minimally Invasive and Robotic Surgery, Transplantation Service, Federico II University Naples.
Asmita ChopraDepartment of Surgery, Promedica Toledo, Toledo, OH.
Mohammed Abu HilalDepartment of surgery, Poliambulanza Foundation Hospital, Brescia, Italy.
Guido TorzilliDepartment of General Surgery, Humanitas University and Research Hospital, IRCCS, Milan, Italy.
Carlos CorveraDepartment of Surgery, University of California San Francisco, San Francisco, CA.
Adnan AlseidiDepartment of Surgery, University of California San Francisco, San Francisco, CA.
Scott HeltonDepartment of Surgery, Virginia Mason Hospital and Seattle Medical Center, Seattle, WA.
Roberto I TroisiDivision of HPB, Minimally Invasive and Robotic Surgery, Transplantation Service, Federico II University Naples.
Kerri SimoDepartment of Surgery, Promedica Toledo, Toledo, OH.
Claudius ConradDepartment of Surgery, Saint Elizabeth Medical Center, Boston, MA.
Matteo CesconHepatobiliary surgery and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Sean ClearyDepartment of Surgery, Mayo Clinic, Rochester, NY.
Choon H D KwonDepartment of Surgery, Cleveland Clinic, Cleveland, OH.
Alessandro FerreroDepartment of Surgery, Mauriziano Hospital, Turin, Italy.
Giuseppe M EttorreDepartment of Surgery, San Camillo Forlanini Hospital, Rome, Italy.
Umberto CilloDepartment of Surgery, University of Padua, Padua, Italy.
David GellerDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
Daniel CherquiDepartment of Surgery, Paul Brousse Hospital, Villejuif, Paris, France.
Pablo E SerranoDepartment of Surgery, McMaster University, Hamilton, ON, Canada.
Cristina FerroneDepartment of Surgery, Massachusetts General Hospital, Boston, MA.
Vincenzo MazzaferroDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Luca AldrighettiDivision, San Raffaele Hospital, Hepatobiliary Surgery Milan, Italy.
T Peter KinghamDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

objectiveTo compare minimally invasive (MILR) and open liver resections (OLRs) for hepatocellular carcinoma (HCC) in patients with metabolic syndrome (MS).

backgroundLiver resections for HCC on MS are associated with high perioperative morbidity and mortality. No data on the minimally invasive approach in this setting exist. MATERIAL AND

methodsA multicenter study involving 24 institutions was conducted. Propensity scores were calculated, and inverse probability weighting was used to weight comparisons. Short-term and long-term outcomes were investigated.

resultsA total of 996 patients were included: 580 in OLR and 416 in MILR. After weighing, groups were well matched. Blood loss was similar between groups (OLR 275.9±3.1 vs MILR 226±4.0, P =0.146). There were no significant differences in 90-day morbidity (38.9% vs 31.9% OLRs and MILRs, P =0.08) and mortality (2.4% vs 2.2% OLRs and MILRs, P =0.84). MILRs were associated with lower rates of major complications (9.3% vs 15.3%, P =0.015), posthepatectomy liver failure (0.6% vs 4.3%, P =0.008), and bile leaks (2.2% vs 6.4%, P =0.003); ascites was significantly lower at postoperative day 1 (2.7% vs 8.1%, P =0.002) and day 3 (3.1% vs 11.4%, P <0.001); hospital stay was significantly shorter (5.8±1.9 vs 7.5±1.7, P <0.001). There was no significant difference in overall survival and disease-free survival.

conclusionsMILR for HCC on MS is associated with equivalent perioperative and oncological outcomes to OLRs. Fewer major complications, posthepatectomy liver failures, ascites, and bile leaks can be obtained, with a shorter hospital stay. The combination of lower short-term severe morbidity and equivalent oncologic outcomes favor MILR for MS when feasible.

Indexed as

Carcinoma, HepatocellularLaparoscopyLiver FailureLiver NeoplasmsMetabolic SyndromeAscitesHepatectomyHumansLength of StayPostoperative ComplicationsPropensity ScoreRetrospective Studies

Identifiers

PMID36994755
PMCPMC11218006

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.